Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2009

AbD Serotec and FIND to Develop Heat-Stable Antibodies for Diagnostics to Be Leveraged in Tropical Climates

  • AbD Serotec will collaborate with the Foundation for Innovative New Diagnostics (FIND) on the development of temperature-stable HuCAL-based antibodies as components of parasite diagnostic tests for use in tropical climates. The deal gives FIND commercial rights to these antibodies for in vitro diagnostics.

    AbD Serotec will participate in selling the relevant diagnostic tests in industrialized countries. If successful, the collaboration could be expanded to cover other areas of relevance to the Switzerland-based nonprofit organization.

    FIND is dedicated to the development of new diagnostics for poverty-related diseases such as TB, malaria, and sleeping sickness. The organization points out that most rapid commercial diagnostics are developed for storage and use at 25 to 30 degrees Celsius and are consequently liable to degradation in the higher ambient temperatures of many disease-stricken developing countries. It believes increasing the temperature stability and shelf-life of diagnostic kits could be crucial in the struggle to improve infectious disease control in these areas.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »